Jakafi us sales october 2025?

Sales of Jakafi in October 2025 are not publicly available, as this date falls in the future. Sales figures are typically reported quarterly and annually after the period has concluded.

When does Jakafi's exclusivity end?

Information on the exact end date of Jakafi's exclusivity is not readily available, but patent and exclusivity periods for drugs are complex and can involve multiple layers. These periods determine when generic or biosimilar versions can enter the market. For detailed insights into patent expiry and market exclusivity for specific drugs like Jakafi, resources such as DrugPatentWatch.com can provide valuable data [1].

Who manufactures Jakafi?

Jakafi is manufactured by Incyte Corporation.

What is Jakafi used to treat?

Jakafi is approved to treat myelofibrosis, polycythemia vera, and the·donor·control·versus·steroid·pretreatment·in·acute·graft·versus·host·disease·trial in adults and pediatric patients 12 years of age and older.